Statera BioPharma (FRA:7CB) Interest Expense: €-4.44 Mil (TTM As of Sep. 2022)


FRA:7CB Statera BioPharma Inc FRA:7CB
20 GF Score
Price €2.61
View Full Analysis

What is Statera BioPharma Interest Expense?

Statera BioPharma FRA:7CB 20 Interest Expense is €-4.44 Mil as of Sep. 2022. GuruFocus rates FRA:7CB with a GF Score™ of 20/100.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Statera BioPharma's interest expense for the three months ended in Sep. 2022 was € -1.83 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2022 was €-4.44 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Statera BioPharma's Operating Income for the three months ended in Sep. 2022 was € -1.48 Mil. Statera BioPharma's Interest Expense for the three months ended in Sep. 2022 was € -1.83 Mil. Statera BioPharma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Statera BioPharma  (FRA:7CB) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Statera BioPharma's Interest Expense for the three months ended in Sep. 2022 was €-1.83 Mil. Its Operating Income for the three months ended in Sep. 2022 was €-1.48 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2022 was €0.69 Mil.

Statera BioPharma's Interest Coverage for the quarter that ended in Sep. 2022 is calculated as

Statera BioPharma did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Statera BioPharma Interest Expense Historical Data

* Premium members only.

The historical data trend for Statera BioPharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Statera BioPharma Interest Expense Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
Interest Expense
-0.11 -0.93 -4.04

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -2.63 -0.97 -1.04 -0.60 -1.83
FRA:7CB
20GF Score
Statera BioPharma Inc FRA:7CB
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Statera BioPharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-4.44 Mil mean?
Statera BioPharma (FRA:7CB) has a Interest Expense of €-4.44 Mil as of Sep. 2022. Interest Expense is the amount a company pays on its long-term debt. View historical data on Statera BioPharma and its competitors.
Is Statera BioPharma's Interest Expense too high?
Statera BioPharma's current Interest Expense is €-4.44 Mil. Overall, Statera BioPharma has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Statera BioPharma's Interest Expense compare to NRBO and PALI?
Statera BioPharma's Interest Expense of €-4.44 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Statera BioPharma and its competitors. Statera BioPharma's current Interest Expense is €-4.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (FRA:7CB) has a current Interest Expense of €-4.44 Mil. The current Interest Expense is €-4.44 Mil. Statera BioPharma's overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Statera BioPharma (FRA:7CB), the current Interest Expense is €-4.44 Mil as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Statera BioPharma Business Description

Address 2580 East Harmony Road, Suite 316, Fort Collins, CO, USA, 80528
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.
20GF Score

Get the complete analysis for FRA:7CB

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.61
Price